........ 13 1.2.2 Brachyury Expression in Cancer and Its Use as an Immunotherapy Target .............. 13 1.2.3 CEA Expression in Cancer and Its Use as an Immunotherapy Target ....................... 14 1.2.4 MUC1 Expression in Cancer and Its Use as an Immunotherapy Target .................... 15 1.2.5 Adenovirus -Based V ectors ................................ ................................ ......................... 15 1.2.6 Clinical Experience with an Ad5 [E1 -, E2b -]-based Cancer Immunotherapy Vaccine 16 1.2.7 ETBX -081 Preclinical Studies ................................ ................................